From [HERE] Here is a high-level review of the manufacturing contracts between US DOD and Moderna. 

Moderna’s injection, mRNA-1273 is co-owned with the US Government, as the company has been funded by the defense research grants for years and also received intellectual property transfers from the US Government, in addition to preclinical and clinical research work conducted for Moderna by the NIH Vaccine Research Center. The NIH and Moderna each have a separate Investigational New Drug number for this product.

Moderna entered 2 types of contracts with the US Government for Spikevax injection:

• “Vaccine” contract and amendments that specifies R&D projects that the US Government ordered and paid for. Note that in Pfizer’s case no R&D activities were ordered or paid for by the US Government, as these were excluded from the scope of the contract.

• “Manufacturing” contract(s) that ordered a large-scale manufacturing. This is different from Pfizer manufacturing contracts as the words “demonstration” and “prototype” are not used. I believe this is because OTA contracts must be for prototypes but FAR contracting doesn’t have to be.

Note on redactions. In both Moderna and Pfizer’s contracts many areas are redacted indicating a reason for redaction – the “redaction codes.” Redacted content has been given codes b (4) and b (6), standing for:

(b) (4) Disclosure of information that would affect the application of advanced technology in a U.S. weapons system,

and

(b) (6) Disclosure of information, including information of foreign governments, that would cause serious harm to relations between the United States and a foreign government or to ongoing diplomatic activities of the United States.

There are several versions of the contract available, plus amendments. The first version was signed on August 9, 2020 and the last available version is June 15, 2021. In one of them the name of the signatory on the Moderna side was redacted with (b)(6). In another version it’s unredacted – it was Hamilton Bennett, a senior director of vaccine access and partnerships. [MORE]